NCT02447991View on ClinicalTrials.gov

Rizatriptan for Episodic Dizziness in Vestibular Migraine

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

July 31, 2020

Study Completion Date

July 31, 2020

Conditions
Vestibular MigraineMigrainous Vertigo
Interventions
DRUG

Rizatriptan

During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.

DRUG

Placebo

During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.

Trial Locations (3)

10029

ICAHN School of Medicine at Mount Sinai, New York

55905

Mayo Clinic, Rochester

90095

University of California, Los Angeles, Los Angeles

All Listed Sponsors
lead

Robert W. Baloh

OTHER

NCT02447991 - Rizatriptan for Episodic Dizziness in Vestibular Migraine | Biotech Hunter | Biotech Hunter